response evaluation criteria in solid tumors · esponse valuation riteria n olid umors recist- the...
TRANSCRIPT
Response Evaluation Criteria in Solid Tumors
o RECIST 1.1 Rules & Definitions o RECIST Resources
o Protocol, Forms o Presentation slides o Example Case
o CT Scans, Forms o Background Article o Certificate
o Introduction and definitions o Resources o Baseline Reporting o Follow-up Reporting o Multi-step studies o Special Circumstances o Wrap up
ESPONSE
VALUATION
RITERIA
N
OLID
UMORS
RECIST- the criteria used to assess impact of a treatment on disease
RECIST 1.0 vs. RECIST 1.1
http://www.ecog.org/ecoginst/Recist.html
For RECIST 1.0 criteria visit:
Disease Definitions Target
Non-target
Response Definitions Complete Response
Partial Response
Progressive Disease
Stable Disease
Measurable lesions
There are different rules for nodal
target lesions and non-nodal target
lesions.
Non-nodal target lesions must be:
> 10 mm long axis when evaluated with CT Scan
> 20 mm long axis when evaluated with Chest X-ray
> 10 mm long axis with calipers
Lymph Nodes:
> 15 mm short axis
for target
Pathologic lesions too small to be considered target lesions
Lesions not qualifying as target lesions due to restrictions on the
number of target lesions from a single site or total number of target
lesions
Truly non-measurable lesions
Bone lesions
Pleural\pericardial effusion and ascites
Inflammatory breast disease
Lymphangitis cutis/pulmonis
Cystic lesions
Leptomeningeal disease
Disappearance of all non-nodal target lesions
Reduction in short axis of all nodal target and nodal
non-target lesions to < 10mm
Disappearance of all non-nodal non-target lesions
A 30% decrease in the Sum of Axes of Target Lesions
(SATL) when compared to the baseline sum
AND
A response of non-PD in non-target lesions
A 20% increase in the (SATL) when compared to the
smallest SATL ever reported
AND
A > 5mm increase over that SATL
And/Or
Presence of new lesions*
* Specific requirements discussed later
Criteria for CR,PR or PD are not met
Section 6.0 of the protocol defines the minimum time
frame required between the start of treatment and
follow-up scan for SD to be reported
Disease Definitions
Target Lesions
• Nodal vs. non-nodal
Non-target Lesions
Response Definitions
Complete Response
Partial Response
Progressive Disease
Stable Disease
Protocol Section 3.0, 6.0 and 7.0
Forms Packet Forms Submission Schedule
RECIST 1.1 Measurement Form
Section 3.0
Section 6.0
Section 7.0
Patient must have measurable or non-measureable
disease.
Baseline measurement and evaluation of all sites of
disease must be obtained < 4 weeks prior to
registration.
Target lesion restrictions
2 target lesions per organ
5 target lesions in total
Lesions with longest axes and are suitable for
repeated measurements
Stable disease minimum time
frame
6 weeks (42 days) from study
entry
Note: Be sure you know
whether the time frame start
from Baseline scans or Study
entry (registration)
Forms Submission
Schedule
Used when reviewing imaging studies to ensure target and non-target
lesions are followed consistently & to determine response
http://www.ecog.org/ecoginst/tools/RECIST_meas_form1_1.pdf
The Purpose
Baseline Reminders
Determining what to report
How to report it
Cross checking forms
Determine patient’s eligibility
Be sure all sites of disease are captured
Ensure follow-up will be done
consistently
ALL sites of disease MUST be reported
(including suspicious sites)
Lesions must be scanned within 4 weeks
of registration
Check your protocol for acceptable
methods of evaluation
Lesions must be followed with the same
method of evaluation used at baseline
E5508 S, J 1 2 3 4 5 Dr. Example
RUL lung #1 LLL lung
Pleural Eff
01/25/2012
54mm 25mm 19mm 16mm
01/25/2012
RUL lung #2
PTrach node 18mm 17mm
1 2 3 4 5 LABEL 1
x
2
1 R upper lobe lung #1 0 9 0 3 0 1 2 5 2 0 1 2 5 4
7 3
2 L lower lobe lung 0 9 0 3 0 1 2 5 2 0 1 2 1 9
73 + 17 = 90mm
3 Paratracheal lymph node 1 0 0 3 0 1 2 5 2 0 1 2 1 7
1 7
9 0
R upper lobe lung #2 0 9 0 3 Pleural Effusion 0 4 0 3 3
0 1 2 5 2 0 1 2
0 1 2 5 2 0 1 2
1 R upper lobe lung #1
0 9 0 3 0 1 2 5 2 0 1 2 5 4
2 L lower lobe lung 0 9 0 3 0 1 2 5 2 0 1 2 1 9
3 Paratracheal lymph node 1 0 0 3 0 1 2 5 2 0 1 2 1 7
R upper lobe lung #2 0 9 0 3 Pleural Effusion 0 4 0 3 3
0 1 2 5 2 0 1 2
0 1 2 5 2 0 1 2
0 2
0 2
0 1
0 2
0 2
0 1
0 1
0 1
0 1
0 1
0 1
0 1
0 2 Pleural effusion
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
SATL: 90mm
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
SATL: 90mm
SATL X 0.7 =
70% of SATL PR < 63.0mm
PD > 108.0mm 90mm X 0.7 = 63.0mm
SATL X 1.2 =
120% of SATL (20% increase over SATL)
90mm X 1.2 = 108.0mm
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
63.0mm
108.0mm
00 mm
SATL: 90mm PR < 63.0mm
PD > 108.0mm
The Purpose
Follow-up Reminders
How to determine overall response
Reporting follow-up scans
Step 1 Baseline
Scan
St 1 Reg
Step 1, Cycle 2 scan
Step 1, Cycle 4
scan
Overall Response
Target Lesions
Non-target Lesions
New Lesions
The lesions must be reported consistently
Same order, number, name and site code
The method of evaluation must be the
same as Baseline
Stable disease minimum time frame must
be met
St 1 Reg
Step 1, Cycle 2 scan 1
2
3
4
5
6
Are confirmation scans required?
E5508 = No confirmation scans
Progression requires the patient to come
off study
Progression exceptions and notes
PD in Effusion/Ascites
Positive cytology must be
obtained
PD in Non-targets only
Must document that the
progression represents the
patients overall disease
status change
PD in new Lymph
Node lesions
Subclinical LNs present
at baseline must
increase to > 15mm or
have pathological
confirmation of
disease in order to be
considered new lesions
Step 1 Baseline
Scan
St 1 Reg
Step 1, Cycle 2 scan
Step 1, Cycle 4
scan
E5508 S, J 1 2 3 4 5 Dr. Example
RUL lung #1 LLL lung
Pleural Eff
01/25/2012
54mm 25mm 19mm 16mm
01/25/2012
RUL lung #2
PTrach node 18mm 17mm
03/15/2012
49mm 19mm 17mm 13mm
03/15/2012
17mm 16mm
Stable Stable
1 2 34 5 LABEL
1
x
1 R upper lobe lung #1 0 9 0 3 0 3 1 5 2 0 1 2 4 9
6 6
2 L lower lobe lung 0 9 0 3 0 3 1 5 2 0 1 2 1 7
66 + 16 = 82mm
3 Paratracheal lymph node 1 0 0 3 0 3 1 5 2 0 1 2 1 6
1 6
8 2
R upper lobe lung #2 0 9 0 3 Pleural Effusion 0 4 0 3 3
0 3 1 5 2 0 1 2
0 3 1 5 2 0 1 2
2
2
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Partial Response is a 30% decrease from the Baseline SATL Progression is a 20% increase from the smallest SATL ever reported
Step 1, Cycle 2 03/15/2012
SATL: 82mm
SATL: 90mm PR < 63.0mm
PD > 108.0mm
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Step 1, Cycle 2 03/15/2012
SATL: 82mm
SATL: 90mm PR < 63.0mm
PD > 108.0mm
SATL X 0.7 =
70% of SATL
90mm X 0.7 = 63.0mm
SATL X 1.2 =
120% of SATL (20% increase over SATL)
90mm X 1.2 = 108.0mm
63.0mm
108.0mm
00 mm
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Step 1, Cycle 2 03/15/2012
SATL: 82mm
SATL: 90mm PR < 63.0mm
PD > 108.0mm
Overall Response
Target Lesions
Non-target Lesions
New Lesions
sd
non no
0 3
0 1
Partial Response is a 30% decrease from the Baseline SATL Progression is a 20% increase from the smallest SATL ever reported
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Step 1, Cycle 2 03/15/2012
SATL: 82 mm Stable Disease
BASELINE: 90mm Step1/Cycle2: 82mm
PR < 63.0mm
PD > 108.0mm SATL: 90mm
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Step 1, Cycle 2 03/15/2012
SATL: 82 mm Stable Disease
PR < 63.0mm
PD > 98.4mm
PR < 63.0mm
PD > 108.0mm
SATL X 1.2 =
120% of SATL (20% increase over SATL)
82mm X 1.2 = 98.4mm
SATL: 90mm
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Step 1, Cycle 2 03/15/2012
SATL: 82 mm Stable Disease
PR < 63.0mm
PD > 98.4mm
63.0mm
98.4mm
00 mm
SATL: 90mm PR < 63.0mm
PD > 108.0mm
Step 1 Baseline
Scan
St 1 Reg
Step 1, Cycle 2 scan
Step 1, Cycle 4
scan
E5508 S, J 1 2 3 4 5 Dr. Example
RUL lung #1 LLL lung
Pleural Eff
01/25/2012
54mm 25mm 19mm 16mm
01/25/2012
RUL lung #2
PTrach node 18mm 17mm
03/15/2012
49mm 19mm 17mm 13mm
03/15/2012
17mm 16mm
Stable Stable
04/26/2012
34mm 15mm 11mm 9mm
04/26/2012
12mm 11mm
Resolved Stable
1 2 34 5 LABEL
1
x
1 R upper lobe lung #1 0 9 0 3 0 4 2 6 2 0 1 2 3 4
4 5
2 L lower lobe lung 0 9 0 3 0 4 2 6 2 0 1 2 1 1
1 0 0 3 0 3 1 5 2 0 1 2 1 1
45 + 11 = 56mm
5 6
3 Paratracheal lymph node
1 1
R upper lobe lung #2 0 9 0 3 0 4 2 6 2 0 1 2 1 Pleural Effusion 0 4 0 3 0 4 2 6 2 0 1 2 2 3
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Step 1, Cycle 2 03/15/2012
SATL: 82 mm
SATL: 90mm PR < 63.0mm
PD > 108.0mm
Stable Disease
PR < 63.0mm
PD > 98.4mm
63.0mm
98.4mm
00 mm
Step 1, Cycle 4 04/26/2012
SATL: 56 mm
Overall Response
Target Lesions
Non-target Lesions
New Lesions
pr
non no
0 2
0 1
pt # 12345 S, J reg date: 02/01/2012
Step 1 Baseline 01/25/2012
Partial Response
Step 1, Cycle 4 04/26/2012
SATL: 56 mm
Step 1, Cycle 2 03/15/2012
SATL: 82 mm
SATL: 90mm PR < 63.0mm
PD > 108.0mm
Stable Disease
PR < 63.0mm
PD > 98.4mm
Step 2 Baseline
Step 2 Follow-up
E5508 S, J 1 2 3 4 5 Dr. Example
RUL lung #1 LLL lung
Pleural Eff
01/25/2012
54mm 25mm 19mm 16mm
01/25/2012
RUL lung #2
PTrach node 18mm 17mm
03/15/2012
49mm 19mm 17mm 13mm
03/15/2012
17mm 16mm
Stable Stable
04/26/2012
34mm 15mm 11mm 9mm
4/26/2012
12mm 11mm
Resolved Stable
E5508 S, J 1 2 3 4 5 Dr. Example
RUL lung #1 LLL lung
Pleural Eff
PTrach node
04/26/2012
34mm 15mm 11mm 9mm
04/26/2012
1 R upper lobe lung #1
0 9 0 3 0 4 2 6 2 0 1 2 3 4
4 5
2 L lower lobe lung
0 9 0 3 0 4 2 6 2 0 1 2 1 1
4 5
Pleural Effusion 0 4 0 3 0 4 2 6 2 0 1 2 3
Paratracheal node 1 0 0 3 0 4 2 6 2 0 1 2
1 R upper lobe lung #1
0 9 0 3 0 4 2 6 2 0 1 2 3 4
2 L lower lobe lung
0 9 0 3 0 4 2 6 2 0 1 2 1 1
Pleural Effusion 0 4 0 3 0 4 2 6 2 0 1 2 3 Paratracheal node 1 0 0 3 0 4 2 6 2 0 1 2
Step 2, Cycle 2 scan
St 2 Reg
Step 1, Cycle 4 scan & Step 2
Baseline
pt # 12345 S, J reg date: 04/27/2012
Step 2 Baseline 04/26/2012
SATL: 45mm
pt # 12345 S, J reg date: 04/27/2012
Step 2 Baseline 04/26/2012
SATL: 45mm PR < 31.5mm
PD > 54.0mm
SATL X 0.7 =
70% of SATL
45mm X 0.7 = 31.5mm
SATL X 1.2 =
120% of SATL (20% increase over SATL)
45mm X 1.2 = 54.0mm
31.5mm
54mm
00 mm
pt # 12345 S, J reg date: 04/27/2012
Step 2 Baseline 04/26/2012
SATL: 45mm PR < 31.5mm
PD > 54.0mm
Step 2, Cycle 2 scan
St 2 Reg
Step 1, Cycle 4 scan & Step 2
Baseline
E5508 S, J 1 2 3 4 5 Dr. Example
RUL lung #1 LLL lung
Pleural Eff
PTrach node
04/26/2012
34mm 15mm 11mm 9mm
04/26/2012
06/21/2012
06/21/2012
37mm 19mm 13mm 12mm
Stable Stable
LABEL
x
1 2 34 5
1
1 R upper lobe lung #1
0 9 0 3 0 6 2 1 2 0 1 2 3 7
5 0
2 L lower lobe lung
0 9 0 3 0 6 2 1 2 0 1 2 1 3
5 0
Paratracheal Node 1 0 0 3 0 6 2 1 2 0 1 2 2
3 Pleural Effusion 0 4 0 3 0 6 2 1 2 0 1 2 2
Right upper lobe lung 0 9 0 3 0 6 2 1 2 0 1 2
2
Right lower lobe lung 0 9 0 3 0 6 2 1 2 0 1 2
31.5mm
54.0mm
00 mm
pt # 12345 S, J reg date: 04/27/2012
Step 2 Baseline 04/26/2012
Step 2, Cycle 2 06/21/2012
SATL: 50mm
SATL: 45mm PR < 31.5mm
PD > 54.0mm
Overall Response
Target Lesions
Non-target Lesions
New Lesions
sd
non yes
0 4
0 2
0 6 2 1 2 0 1 2
All lesions were not evaluated
Minimum SD time was not met
Patient had a resection
Two lesions merged into one
One lesion split
Lesion is too small to measure
◦ If SATL of evaluated lesions shows > 20% increase in smallest SATL reported since baseline
Provide the SATL on the form
Target lesion response: PD
Overall response: PD
Overall Response: PD
PD > 75.6
If SATL of evaluated lesions shows < 20% increase in smallest SATL reported since baseline
◦ Do not report SATL on the form ◦ Overall response: -1 = Insufficient
Unless PD in non-target lesions or appearance of new lesions is reported then code PD
Overall Response: -1 = Insufficient Evaluation
PD > 75.6
If subject does not have a PR, CR or PD, be sure minimal timeline is met (section 6.0) before coding SD Section 6.0 stated “…6 weeks” If interval not met. This should be coded as -1
Continue to submit Follow-up RECIST 1.1 forms
Resected target lesion should be reported as 0 mm at each cycle
Resected non-target lesions should have a follow-up status of [1] = CR at each cycle
Continue to code overall response until PD Be sure to add comment
Continue to report all target lesions in the same order as reported at baseline—even if merged.
Find longest/shortest axis of merged lesion; divide measurement by # of original lesions
Report this calculation as the measurement for each original lesion
Be sure to add comment
Example: Cycle 2: TL #1: 30 mm TL #2: 20 mm Cycle 4: These lesions have merged to one lesion
measuring 60 mm 60 / 2 (# of original lesions) = 30 mm On the form report: TL#1: 30 mm TL #2: 30 mm
Continue to report the original target lesion as it was reported at baseline.
◦ Do not report them separately or as new lesions
Calculate the sum of the longest/shortest axes of both lesions and report this sum as the measurement for the original lesion.
Be sure to add comment
Example: Cycle 2: TL #1: 50 mm Cycle 4: This lesion has split into two lesions, one
measuring 20 mm and the other 10 mm 20 + 10 = 30 mm On the form report: TL#1: 30 mm
If a lesion becomes too small to measure but has not disappeared, code it as 1 mm.
These 2 lesions merged
All lesions were not evaluated!
But the minimum time requirement for SD was not met!
What if the patient had a resection?
This lesion split into two! The lesion is too
small to measure
Common “special circumstances”
Know the protocol requirement • Measurable vs. non-measurable • Assessment requirements
• Baseline • During protocol therapy
• Stable disease timeline
Use worksheets!! Work with the MD!!
RECIST 1.1 REMINDERS
Follow all lesions consistently • Assess all lesions at each evaluation • Use the same method of evaluation from Baseline to Follow-Up • Record all lesions even if not evaluated
RECIST 1.1 REMINDERS
Call ECOG CC 617-632-3610
Any Question?!